Novonesis (0Q4U) Price & Analysis

0Q4U Stock Chart & Stats

DKK 464.80-DKK 0.74(-0.16%)

At close: Oct 30 4:00 PM EDT

Day’s Range: DKK 464.50 - DKK 470.60
52-Week Range: DKK 337.50 - DKK 481.50
Previous Close: DKK 465.54
Volume: 19.32K
Average Volume (3M): 157.47K
Market Cap: DKK 215.42B
Enterprise Value: DKK 213.11B
Total Cash (Recent Filing): DKK 256.50M
Total Debt (Recent Filing): DKK 1.70B
Price to Earnings (P/E): 44.2
Beta: 0.53
Next Earnings: Nov 05, 2026
EPS Estimate: 4.96
Next Dividend Ex-Date: N/A
Dividend Yield: 1.42%

Novonesis News

Novonesis completes acquisition of MicroBioGen

Novonesis (NVZMY) announced the completion of its acquisition of MicroBioGen. All regulatory approvals have been obtained, and the transaction has closed. The acquisition builds on Novonesis’ investment in MicroBioGen in

1M agoNZM NVZMY

Novonesis price target raised to DKK 530 from DKK 440 at Citi

Citi analyst Ranulf Orr raised the firm’s price target on Novonesis (NVZMY) to DKK 530 from DKK 440 and keeps a Buy rating on the shares. Published first on TheFly

1M agoNZM NVZMY

Novonesis price target raised to DKK 540 from DKK 520 at JPMorgan

JPMorgan raised the firm’s price target on Novonesis (NVZMY) to DKK 540 from DKK 520 and keeps an Overweight rating on the shares. Over the past roughly 18 months, Novonesis

1M agoNZM NVZMY

Novonesis price target raised to DKK 500 from DKK 422 at Berenberg

Berenberg raised the firm’s price target on Novonesis (NVZMY) to DKK 500 from DKK 422 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate

2M agoNZM NVZMY

Novonesis price target raised to DKK 535 from DKK 520 at Morgan Stanley

Morgan Stanley analyst Lisa De Neve raised the firm’s price target on Novonesis (NVZMY) to DKK 535 from DKK 520 and keeps an Overweight rating on the shares. Published first

2M agoNZM NVZMY

0Q4U Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Novonesis A/S (UK) (0Q4U) is scheduled to report 2nd quarter earnings on 08/20/2026. Regarding Q2 estimates, Wall Street analysts expect Novonesis A/S (UK) to post earnings of €0.53 per share.

2M agoNZM2 0Q4U

Novonesis price target raised to DKK 520 from DKK 500 at JPMorgan

JPMorgan analyst Chetan Udeshi raised the firm’s price target on Novonesis (NVZMY) to DKK 520 from DKK 500 and keeps an Overweight rating on the shares. Published first on TheFly

3M agoNZM NVZMY

Novonesis upgraded to Neutral from Underperform at BNP Paribas

BNP Paribas upgraded Novonesis (NVZMY) to Neutral from Underperform with a price target of DKK 415, up from DKK 362. The firm cites valuation following the stock’s recent pullback for

4M agoNZM NVZMY

Novonesis price target raised to DKK 490 from DKK 480 at Deutsche Bank

Deutsche Bank analyst Virginie Boucher-Ferte raised the firm’s price target on Novonesis (NVZMY) to DKK 490 from DKK 480 and keeps a Buy rating on the shares. Published first on

4M agoNZM NVZMY

Novonesis price target lowered to DKK 552 from DKK 560 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Novonesis (NVZMY) to DKK 552 from DKK 560 and keeps an Overweight rating on the shares. Published first on TheFly – the

5M agoNZM NVZMY

Novonesis upgraded to Buy from Hold at Kepler Cheuvreux

Kepler Cheuvreux analyst Patrick Roquas upgraded Novonesis (NVZMY) to Buy from Hold with a price target of DKK 460, up from DKK 390. The firm says the company has the

5M agoNZM NVZMY

Novonesis A/S (UK) (0Q4U) Q1 Earnings Cheat Sheet

Novonesis A/S (UK) (0Q4U) is scheduled to report 1st quarter earnings on 05/05/2026. Regarding Q1 estimates, Wall Street analysts expect Novonesis A/S (UK) to post earnings of €0.70 per share.

6M agoNZM2 0Q4U

0Q4U Earnings this Week: How Will it Perform?

Novonesis A/S (UK) (0Q4U) is scheduled to report 4th quarter earnings on 02/25/2026, before the market opens. Regarding Q4 estimates, Wall Street analysts expect Novonesis A/S (UK) to post earnings

8M agoNZM2 0Q4U

0Q4U Upcoming Earnings Report: What to Expect?

Novonesis A/S (UK) (0Q4U) is scheduled to report 2nd quarter earnings on 08/21/2025, before the market opens. Regarding Q2 estimates, Wall Street analysts expect Novonesis A/S (UK) to post earnings

1y agoNZM2 0Q4U

0Q4U FAQ

What was Novonesis’s price range in the past 12 months?

Novonesis lowest share price was kr 337.50 and its highest was kr 481.50 in the past 12 months.

What is Novonesis’s market cap?

Novonesis’s market cap is kr 215.42B.

When is Novonesis’s upcoming earnings report date?

Novonesis’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.

How were Novonesis’s earnings last quarter?

Novonesis released its earnings results on Aug 19, 2026. The company reported kr 2.84 earnings per share for the quarter, missing the consensus estimate of kr 4.036 by -kr 1.196.

Is Novonesis overvalued?

According to Wall Street analysts Novonesis’s price is currently Undervalued.

Does Novonesis pay dividends?

Novonesis does not currently pay dividends.

What is Novonesis’s EPS estimate?

Novonesis’s EPS estimate is 4.96.

How many shares outstanding does Novonesis have?

Novonesis has 414,555,050 shares outstanding.

What happened to Novonesis’s price movement after its last earnings report?

Novonesis reported an EPS of kr 2.84 in its last earnings report, missing expectations of kr 4.036. Following the earnings report the stock price went up 0.302%.

Which hedge fund is a major shareholder of Novonesis?

Currently, no hedge funds are holding shares in GB:0Q4U

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Novonesis

Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends internationally, serving markets in Denmark, the rest of Europe, North America, Asia Pacific, the Middle East, Africa, and Latin America. Novozymes' diverse portfolio includes protein solutions for the food and beverage sector, alongside a comprehensive suite of cleaning and hygiene offerings for industrial, medical, and household applications, such as drain openers, septic tank treatments, ware washing, and professional laundry. In agriculture, they supply solutions for various crops like corn, cotton, soybeans, and wheat, focusing on bioyield and biocontrol, in addition to animal health and nutrition products and aquaculture systems for warm water species. The company actively supports sustainable industrial processes with contributions to bioenergy (including ethanol, biodiesel, renewable diesel, biogas, and wastewater treatment), biorefining (encompassing fiber modification, bleach boosting, deposit control, starch modification, carbon capture), and applications for textiles and leather. Their extensive range of enzyme solutions, such as lipases, proteases, oxidoreductases, and carbohydrases, are crucial for processes like corn and wheat separation, liquefaction, and saccharification. Furthermore, Novozymes addresses human health with solutions targeting brain, oral, protective, immune, and gastrointestinal well-being, while also engaging in areas like biocatalysis, cell culture, and diagnostics.

Novonesis (0Q4U) Earnings & Revenues

Historic Earnings Reports

0Q4U Net sales Breakdown

28.53% Household Care
24.83% Bioenergy
22.07% Food, Beverages & Human Health
12.82% Grain & Tech Processing
11.75% Agriculture & Animal Health

0Q4U Stock 12 Month Forecast

Average Price Target

DKK 524.17▲(12.77% Upside)

Past 12 Months12 Month ForecastJan2026Oct2026

HighDKK 540.00

AverageDKK 524.17

LowDKK 500.00

Detailed Analyst Forecast >

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	12	6	4
Technical Analysis	3	6	1
Moving Averages	9	0	3

Technical Analysis >

Ownership Overview

5.78% Mutual Funds
0.01% Other Institutional Investors
83.34% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

Novonesis stock analysis

Novonesis (0Q4U) Price & Analysis

0Q4U Stock Chart & Stats

Novonesis News

Novonesis completes acquisition of MicroBioGen

Novonesis price target raised to DKK 530 from DKK 440 at Citi

Novonesis price target raised to DKK 540 from DKK 520 at JPMorgan

Novonesis price target raised to DKK 500 from DKK 422 at Berenberg

Novonesis price target raised to DKK 535 from DKK 520 at Morgan Stanley

0Q4U Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Novonesis price target raised to DKK 520 from DKK 500 at JPMorgan

Novonesis upgraded to Neutral from Underperform at BNP Paribas

Novonesis price target raised to DKK 490 from DKK 480 at Deutsche Bank

Novonesis price target lowered to DKK 552 from DKK 560 at Morgan Stanley

Novonesis upgraded to Buy from Hold at Kepler Cheuvreux

Novonesis A/S (UK) (0Q4U) Q1 Earnings Cheat Sheet

0Q4U Earnings this Week: How Will it Perform?

0Q4U Upcoming Earnings Report: What to Expect?

0Q4U FAQ

Company Description

Novonesis

Novonesis (0Q4U) Earnings & Revenues

0Q4U Net sales Breakdown

0Q4U Stock 12 Month Forecast

Average Price Target

Technical Analysis

Overall Consensus

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium